“…The intracellular pathogen L. pneumophila has the largest studied bacterial effector arsenal with over 300 effectors (Burstein et al , 2009; Huang et al , 2011; Zhu et al , 2011) and notably has several of such regulatory layers; indirect antagonist effectors (Müller et al , 2010; Neunuebel et al , 2011; Mukherjee et al , 2011; Tan & Luo, 2011; Tan et al , 2011; Valleau et al , 2018; Gan et al , 2019a; Wan et al , 2019; Gan et al , 2020; Song et al , 2021), cooperative paraeffectors (Schator et al , 2023) and several metaeffectors (Kubori et al , 2010; Jeong et al , 2015; Urbanus et al , 2016; Shames et al , 2017; Valleau et al , 2018; Bhogaraju et al , 2019; Black et al , 2019; Gan et al , 2019b; Joseph et al , 2020; Hsieh et al , 2021; McCloskey et al , 2021; Song et al , 2021), including the effector LubX for which the term metaeffector was coined (Kubori et al , 2010). L. pneumophila is the causative agent of Legionnaires’ disease (Fields et al , 2002) and uses the Dot/Icm Type IVB secretion system (T4SS) to deliver effectors to create a replicative niche in macrophages (Isberg et al , 2009) and protozoan species (Fields, 1996; Rowbotham, 1980; Molmeret et al , 2005; Faulkner et al , 2008; Watanabe et al , 2016; Boamah et al , 2017; Siddiqui et al , 2021).…”